NECTIN4 and neoplasm: Therefore, they developed PDCs that can target both Nectin-4 and CD137, namely BT7480, which, due to its high affinity for Nectin-4 and CD137, can bring CD137-positive immune cells into contact with Nectin-4-positive tumor cells simultaneously, thereby activating the immune cells to exert anti-tumor effects.